Resilient Merck stock trades at a 12-month high as fresh FDA approvals and Q2 2026 growth support the outlook

Merck & Co., Inc. (US58933Y1055) stock is trading close to a new 12-month high in mid-August 2026, with recent quotes around $135.84 on the New York Stock Exchange as of August 17, 2026 and a market value reported at $335.8 billion.

The shares have climbed 69.7% over the past year while a string of clinical and regulatory milestones, including a new U.S. Food and Drug Administration approval for Merck’s KEYTRUDA branded immunotherapies in muscle-invasive bladder cancer announced on August 17, 2026, provides a fresh catalyst for investors. Per a same-day analyst overview, the stock now carries a consensus 1-year price target of $135.50 and an average rating in the moderate buy range with most firms recommending the shares.

Shares hold close to a 12-month high

Recent market data compiled on August 17, 2026 show Merck stock quoted at $135.84 intraday, modestly above the prior closing price of $135.78 on August 14, 2026, which corresponds to a daily percentage gain of 0.23% in the latest regular session. A real-time quote snapshot indicates that the shares trade very close to their disclosed 12-month high of $135.97, underlining the strength of the latest rally.

In a separate performance overview, Merck’s equity is described as having delivered a 69.7% price increase over the past 12 months while the company’s market capitalization stands near $335.8 billion as of mid-August 2026. A large-cap performance screen places Merck among 17 sizeable companies marking new 52-week highs, with Merck’s one-day move at 0.2% and 1-week and 1-month gains of 5.6% and 6.4%, respectively, reinforcing the momentum narrative.

Analysts lift targets after Q2 2026 growth

An August 17, 2026 research summary indicates that twenty-two analyst firms now cover Merck stock, with fifteen assigning buy recommendations and seven opting for hold ratings, resulting in an average rating described as moderate buy and a consensus 1-year price target of $135.50. An analyst-consensus overview notes that institutional investors and hedge funds own more than three quarters of the company’s outstanding shares, pointing to robust institutional participation.

On the same date, a separate report highlights that Daiwa Securities upgraded Merck from neutral to outperform and raised its price target from $120 to $143, a lift of $23 that places the new target 5.3% above the stock’s latest quoted price of $135.84. A valuation and dividend analysis explains that this upgrade follows encouraging clinical trial results for sacituzumab tirumotecan, a TROP2-targeted antibody-drug conjugate Merck expects to launch in fiscal 2027, and frames Merck as trading 13.3% above a GF Value metric of $119.85 based on a current price reference of $135.84.

The same valuation commentary points out that despite the perceived 13.3% overvaluation versus the GF Value benchmark, the analyst community continues to support Merck’s long-term earnings and dividend story, given its oncology pipeline and cash generation. The implied upside between the consensus target of $135.50 and Daiwa’s raised $143 target shows a range of views about the stock’s potential, but both are anchored in expectations that recent revenue growth and pipeline developments will sustain future cash flows.

KEYTRUDA gains fresh FDA momentum

The fundamental backdrop behind the latest stock strength has been reinforced by immune-oncology approvals. On August 17, 2026, Merck announced that the U.S. Food and Drug Administration approved KEYTRUDA and KEYTRUDA QLEX, both anti-PD-1 therapies, each in combination with Padcev as neoadjuvant treatment continued after cystectomy as adjuvant treatment for adult patients with muscle-invasive bladder cancer. A recent summary of FDA events notes that this dual-therapy approval strengthens Merck’s position in bladder cancer by expanding both its KEYTRUDA and KEYTRUDA QLEX franchises.

This new approval is strategically important because it both deepens KEYTRUDA’s presence in earlier-stage disease settings and supports Merck’s efforts to maintain growth in its oncology portfolio as competitive pressure in immunotherapy intensifies. Earlier in August 2026, KEYTRUDA was granted a Canadian approval in muscle-invasive bladder cancer, and the combination of U.S. and Canadian regulatory decisions within the same month underpins Merck’s regional revenue prospects in this specific indication. Across its business, Merck’s management has highlighted oncology and animal health as key pillars of growth, and the latest bladder cancer approval fits that narrative by adding another evidence-backed use case for its flagship immunotherapy brand.

From an investor’s perspective, the KEYTRUDA and KEYTRUDA QLEX approval provides a tangible near-term driver that can feed into revenue and earnings from fiscal 2027 onward once uptake ramps across eligible bladder cancer patients. The Daiwa price-target increase from $120 to $143 on August 17, 2026 is explicitly linked to promising clinical trial data for sacituzumab tirumotecan, and when combined with the new KEYTRUDA-related approval, investors receive a clearer picture of Merck’s diversified oncology pipeline. These developments help explain why the market is willing to accept a valuation premium of 13.3% against the GF Value benchmark despite concerns around long-term dividend sustainability raised in the same analysis.

Dividend yield and valuation context

Despite the strong share-price performance, Merck still offers an income component. A same-day coverage of Merck’s stock notes an annualized dividend payout of $3.40 per share, which, when compared against the latest $135.84 share price as of August 17, 2026, equates to a forward-looking dividend yield of 2.5%. The stock trades at a price-earnings ratio of 108.62 on recent data, paired with a PEG ratio of 5.86 and a beta of 0.19, suggesting an earnings multiple rich relative to some peers but with relatively low volatility and a valuation that anticipates future pipeline-driven growth rather than near-term earnings alone.

The same analyst-consensus compilation emphasizes that institutional investors and hedge funds collectively hold more than 76% of Merck’s shares, indicating that professional capital is significantly engaged with the stock. For an income-focused investor, the combination of a 2.5% dividend yield and the 69.7% share-price increase over the past year, as documented in the large-cap high list, represents a total-return profile that has outpaced the broader healthcare sector. For valuation-sensitive investors, the 13.3% premium over the GF Value metric at a comparison price of $135.84 opens a debate about whether Merck’s pipeline sufficiently justifies that premium; the Daiwa target of $143 implies a belief that the market has not yet fully discounted future oncology revenues.

A key interpretive point is that Merck’s premium valuation appears closely tied to confidence in late-stage assets like sacituzumab tirumotecan and ongoing indications for KEYTRUDA in multiple cancer types. Under this view, the GF Value reference of $119.85 provides a baseline derived from historical earnings and growth patterns, while the live market price near $135.84 and upgraded targets embed assumptions about incremental cash flows from future launches and label extensions. As long as trial data and regulatory decisions continue to support these growth assumptions, the stock can sustain its premium to GF Value and maintain a moderate buy consensus view.

Representative product - KEYTRUDA immunotherapy

KEYTRUDA is Merck’s flagship PD-1 inhibitor immunotherapy used to treat multiple cancer types, including lung cancer, melanoma, and bladder cancer, and it has become one of the most widely prescribed drugs in the company’s portfolio. With the August 17, 2026 FDA approval, KEYTRUDA and its related formulation KEYTRUDA QLEX will now be used in combination with Padcev as neoadjuvant and adjuvant therapy for adult patients with muscle-invasive bladder cancer undergoing cystectomy, adding another clinically meaningful use case to the brand.

For patients and physicians, this expanded use of KEYTRUDA in bladder cancer provides more flexibility in tailoring treatment plans, arguably improving outcomes in a patient population facing significant risk of progression. From a business perspective, each new indication supports Merck’s revenue base by enlarging the pool of eligible patients and lengthening treatment durations. Across oncology, Merck’s approach has been to continually broaden KEYTRUDA’s label, and the latest approvals fit into this strategy by enhancing its presence in genitourinary cancers alongside existing approvals in other tumor types.

Closing view on Merck stock

As of August 17, 2026, Merck stock is quoted at $135.84 in regular trading, sitting just below its 12-month high of $135.97 and implying a one-year total price gain of 69.7% backed by ongoing strength in oncology and recent bladder cancer approvals. With a market capitalization cited at $335.8 billion, a current dividend yield of 2.5% based on a $3.40 annualized payout, and analyst price targets clustering around $135.50 with some upward revisions to $143, Merck remains a large-cap healthcare name where valuation hinges on continued delivery from its immunotherapy franchise and late-stage pipeline.

Fact box

Company: Merck & Co., Inc.

ISIN: US58933Y1055

Ticker: MRK

Exchange: New York Stock Exchange

Price (as of August 17, 2026, 3:59 p.m. ET): $135.84 USD

Market cap: $335.8 billion (as of August 17, 2026)

Sector / Industry: Health care / Pharmaceuticals

Index membership: S&P 500